- Home
- MGNX vs GCV Comparison
MGNX vs GCV Comparison
Compare MGNX & GCV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNX
- GCV
- Stock Information
- Founded
- MGNX 2000
- GCV 1988
- Country
- MGNX United States
- GCV United States
- Employees
- MGNX N/A
- GCV N/A
- Industry
- MGNX Biotechnology: Pharmaceutical Preparations
- GCV Finance/Investors Services
- Sector
- MGNX Health Care
- GCV Finance
- Exchange
- MGNX Nasdaq
- GCV Nasdaq
- Market Cap
- MGNX 70.3M
- GCV 75.6M
- IPO Year
- MGNX 2013
- GCV N/A
- Fundamental
- Price
- MGNX $1.26
- GCV $3.36
- Analyst Decision
- MGNX Hold
- GCV
- Analyst Count
- MGNX 10
- GCV 0
- Target Price
- MGNX $6.83
- GCV N/A
- AVG Volume (30 Days)
- MGNX 1.1M
- GCV 57.9K
- Earning Date
- MGNX 05-08-2025
- GCV 01-01-0001
- Dividend Yield
- MGNX N/A
- GCV 13.04%
- EPS Growth
- MGNX N/A
- GCV N/A
- EPS
- MGNX N/A
- GCV N/A
- Revenue
- MGNX $149,962,000.00
- GCV N/A
- Revenue This Year
- MGNX N/A
- GCV N/A
- Revenue Next Year
- MGNX $80.86
- GCV N/A
- P/E Ratio
- MGNX N/A
- GCV N/A
- Revenue Growth
- MGNX 155.26
- GCV N/A
- 52 Week Low
- MGNX $0.99
- GCV $3.15
- 52 Week High
- MGNX $17.24
- GCV $4.58
- Technical
- Relative Strength Index (RSI)
- MGNX 34.84
- GCV 34.90
- Support Level
- MGNX $1.10
- GCV $3.35
- Resistance Level
- MGNX $1.34
- GCV $3.59
- Average True Range (ATR)
- MGNX 0.13
- GCV 0.16
- MACD
- MGNX 0.04
- GCV -0.02
- Stochastic Oscillator
- MGNX 77.14
- GCV 46.05
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
About GCV Gabelli Convertible and Income Securities Fund Inc. (The)
GABELLI CONVERTIBLE & INCOME SECURITIES FUND INC is a diversified closed-end management investment company. Its investment objective is to seek a high level of total return through a combination of current income and capital appreciation by investing in convertible securities. The company invests in various portfolios such as Health Care, Financial Services, Real Estate Investment Trust, Energy and Utilities, Telecommunications, Food and Beverage, Aerospace and Automotive and others. All the operation of the group is operated through the regions of United States.